Listen to article
A single-shot Covid-19 vaccine by US drugmaker Johnson and Johnson is likely to be approved for use in the European Union in early March, a French minister confirmed on Sunday.
Recall that the vaccine was earlier cleared for emergency use in the United States on Saturday, which effectively made it become the third available vaccine in the north American heavy weight.
According to the Food and Drug Administration (FDA) in US, the single-shot vaccine is highly effective in preventing severe Covid-19, including against newer variants was possibly why it got the green light.
French Industry Minister Agnes Pannier-Runacher told France 3 television that the European Medicines Agency (EMA) was also evaluating information transmitted by the US pharmaceuticals company.
Read Also: Ghana Receives COVID-19 Vaccine
An EU approval in early March would allow the vaccine to be rolled out in late March or early April, she said, adding this was ‘good news‘ because it offers protection with a single shot in contrast to other vaccines requiring two.
She said it was possible that a booster shot was needed later ‘but we can’t be sure yet’.
According to her, the EU hoped to receive 600 million doses of the vaccine by the end of June.
France has so far vaccinated 1.5 million people, the minister said. By June all 15 million people belonging to the country’s most vulnerable population segments will have been vaccinated, she added, acknowledging however that reaching that target might require a faster vaccine rollout.
In large clinical trials, the J&J vaccine’s efficacy against the severe disease was 85.9 percent in the United States, 81.7 percent in South Africa, and 87.6 percent in Brazil.
The J&J shot appears less protective than Pfizer and Moderna’s two-shot regimens, which both have an efficacy of around 95 percent against all forms of Covid-19 from the classic coronavirus strain.
AFRICA TODAY NEWS, NEW YORK